Early Treatment Pathways Improve Outcomes in Severe Autoimmune Diseases: Systematic Review and Evidence Synthesis of 430 Studies

Tavneos (avacopan) - Amgen

Rituxan (rituximab) - Roche

Nucala (mepolizumab) - GSK

cyclophosphamide - Generic mfg.

nintedanib - Generic mfg.

Actemra IV (tocilizumab) - Roche, JW Pharma, Chugai Pharmaceutical

azathioprine - Generic mfg.

Saphnelo (anifrolumab-fnia) - AstraZeneca

https://eppro02.ativ.me/web/page.php?page=session&project=ACR26&id=3564404

Sara Campos1; Marta Baião1; Paula Mesquita1; Carolina Anjo1; Renata Martinho1; Marta Barrigas1; Beatriz Martinho1; Rita Matos Sousa1; Maria Leonor Neves1; Marta Cunha1; Luísa Viveiros2; Teresa Mendonça1; António Marinho1; Marta Casal Moura2

Sep 8, 2026